Description

Zynerba Pharmaceuticals, Inc. functions as a specialized pharmaceutical entity currently undergoing clinical development. Its primary endeavor is the creation of medicinal cannabinoid treatments, applied transdermally, intended for rare and uncommon neuropsychiatric conditions. Among its key initiatives is the development of Zygel, a pharmaceutical-grade cannabidiol precisely engineered as a gel for enhanced transdermal permeation. Previously known as AllTranz, Inc., the corporation formally adopted the name Zynerba Pharmaceuticals, Inc. in August 2014. Established in 2007, its corporate headquarters are located in Devon, Pennsylvania.